Expression of Heat Shock Protein 105b in Adenocarcinoma of Esophagogastric Junction and Its Relation with Effect of Hyperthermic Intraperitoneal Chemotherapy

• Main Authors: SU Wenzhong, LI Shoumiao, ZHOU Guanghui, WANG Hu, HU Guangjie, HUANG Yanling, LI Li, MA Huabing
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2021-04-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: esophagogastric junction neoplasms; hsp105b; hyperthermic intraperitoneal chemotherapy; clinicopathological characteristics; prognosis
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0824.htm

Objective To explore the expression of heat shock protein (HSP) 105b in advanced adenocarcinoma of esophagogastric junction (AEG) patients and its relation with clinicopathological characteristics and effect of hyperthermic intraperitoneal chemotherapy (HIPEC). Methods We randomly divided 166 cases of advanced AEG who underwent open radical gastrectomy and lymphadenectomy D2 compartment into treatment group (prophylactic HIPEC of paclitaxel after operation) and control group (conventional treatment). Immunohistochemistry was used to detect HSP105b expression in postoperative tumor tissues, and to analyze its relation with clinicopathological characteristics and effect of HIPEC. Results The expression of HSP105b was only associated with tumor vein infiltration (t=4.002, P=0.045). The 3-year disease-free survival rate of the patients with high HSP105b expression was significantly lower than those with low HSP105b expression (56.5% vs. 64.8%, χ2=35.508, P < 0.001), and the disease-free survival rate of the patients with high HSP105b expression in treatment group was significantly lower than that with low HSP105b expression (60.7% vs. 71.5%, χ2=77.459, P < 0.001). Conclusion HSP105b can be used as a prognostic factor and its expression can predict the efficacy of HIPEC in the patients with advanced AEG.